While resistance mechanisms such as elevated KRAS or EGFR activity can lead to emergent drug resistance in some tumours (Huang et al, 2021; Hofmann et al, 2022; Zhang et al, 2018), the primary mode(s) of resistance for many CRC tumours remain unclear. This evidence concerns the gene KRAS and colorectal carcinoma.